Zacks Investment Research on MSN10d
GSK Stock Recovers, Rises Around 17% YTD: Time to Buy, Sell or Hold?
GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also ...
Feds probe tip that Pfizer delayed announcing COVID vaccine’s success until after 2020 election: report
The report said GSK’s former head of vaccine development, Philip Dormitzer, who joined the company after working at ...
Zacks Investment Research on MSN4d
GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection
GSK plc GSK announced that the FDA has approved its oral antibiotic gepotidacin for treating uncomplicated urinary tract ...
pharmaphorum2d
GSK struggles to maintain respiratory dominance
GSK now says earnings in 2014 will be in line with last year, having previously said it expected growth of 4 to 8 per cent. Witty said on the results call that in the last three months the ...
Yahoo Finance3d
Jim Cramer Says ‘Buy and Put Away’ GSK (GSK) for Its 4% Yield
GSK) stands against other stocks that Jim Cramer discussed. On Tuesday, Jim Cramer, host of Mad Money, defended the growing wave of artificial intelligence investment, drawing a distinct line ...
Morningstar4d
GSK's Vaccine and HIV Portfolios Support Ongoing Innovation in Oncology and Immunology
Overall, GSK's established product line creates the enormous cash flows needed to fund the average $800 million in development costs per new drug. A powerful distribution network sets up the ...
FIRST EVER PATIENT DOSED WITH ALPIBECTIR-ETHIONAMIDE IN COMBINATION WITH FIRST-LINE TB DRUGS IN A 14-DAY PHASE 2 CLINICAL TRIAL
Under the BioVersys and GSK collaboration agreement, GSK is evaluating the early bactericidal activity (EBA) of alpibectir-ethionamide (AlpE) in a pulmonary tuberculosis (TB) trial, in combination ...
New York Post4d
FDA greenlights GSK’s drug for UTIs in women and girls
The Food and Drug Administration on Tuesday approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new approvals the British drugmaker ...
The Pharma Letter4d
FDA nod for GSK’s Blujepa for UTIs
Pharma major GSK (LSE: GSK) on Tuesday said its urinary tract infection treatment gepotidacin, under the brand name Blujepa, ...
AOL1mon
GSK could double CEO Emma Walmsley’s pay to $27 million in bid to bring U.K. exec salaries in line with the U.S.
GSK could double its long-serving CEO Emma Walmsley’s pay packet to £21.6 million ($27.2 million) after admitting its boss's current pay didn’t reward her performance and would put off future ...
Yahoo Finance4d
GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection
GSK plc GSK announced that the FDA has approved its oral antibiotic gepotidacin for treating uncomplicated urinary tract infections (uUTIs) in female adults and adolescents. A commercial launch ...
Nasdaq10d
GSK Stock Recovers, Rises Around 17% YTD: Time to Buy, Sell or Hold?
The increase was fueled by the inclusion of potential revenues from Blenrep, multiple new drug/line extension launch opportunities and late-stage pipeline progress. GSK enjoys a strong position in ...